Ipratropium bromide monohydrate Chemical Properties

Melting point:

231 °C

storage temp. 

2-8°C

solubility 

H2O: soluble10mg/mL

form 

powder

color 

white

Stability:

Hygroscopic

InChIKey

KEWHKYJURDBRMN-XSAPEOHZNA-M

SMILES

C([N+]1([C@@H]2C[C@@H](OC(=O)C(C3C=CC=CC=3)CO)C[C@H]1CC2)C)(C)C.[Br-].O |&1:2,4,18,r|

Safety Information

Hazard Codes 

Xn

Risk Statements 

20/22-36

Safety Statements 

26

RTECS 

YM3700000

HS Code 

2939800000

Ipratropium bromide monohydrate Usage And Synthesis

Description

Ipratropium bromide is a quaternary ammonium congener of atropine and is an anticholinergic compound approved for use as a bronchodilator. Anticholinergic agents produce bronchodilatation by antagonizing the activity of acetylcholine at the level of its receptor, particularly those found on airway smooth muscle in the large, central airways. The onset of action of ipratropium is relatively slow (20 minutes), and the peak effect occurs at 60 minutes.1 Ipratropium, unlike atropine, is poorly absorbed across mucous membranes and has little toxicity at the usual doses.

Chemical Properties

White or almost white, crystalline powder.

Uses

Ipratropium bromide monohydrate has been used for the inhibition of peripheral muscarinic receptors in rats.

Uses

antihypertensive

Definition

ChEBI: The monohydrate form of ipratropium bromide. An anticholinergic drug, ipratropium bromide blocks the muscarinic cholinergic receptors in the smooth muscles of the bronchi in the lungs. This opens the bronchi, so providing relief in chronic obstructive pulm nary disease and acute asthma.

brand name

Atrovent (Boehringer Ingelheim).

Biochem/physiol Actions

Ipratropium bromide monohydrate is a nonselective muscarinic acetylcholine receptor antagonist and a bronchodilator. In nebulized form, it is used for treating asthma and obstructive pulmonary diseases. It acts as a β2 adrenoreceptor agonist. Ipratropium bromide monohydrate is an anticholinergic agent and competes with acetylcholine. It promotes bronchodilation by stimulating sympathetic pathways.

Clinical Use

Anticholinergic bronchodilator:

Reversible airways obstruction, particularly in COPD

Side effects

Previous severe allergic reaction symptoms upon using ipratropium or atropine and its other derivatives, such as angioedema, urticaria, severe shortness of breath, oropharyngeal edema, and ultimately anaphylaxis is a contraindication to ipratropium use.
Ipratropium aerosols can cause bronchospasms (paradoxical), which usually happens upon the initial use of this medication

Metabolism

After inhalation, around 10-30% of a dose is deposited in the lungs where it exerts its therapeutic effect. Only a small amount of ipratropium reaches the systemic circulation. The majority of a dose is swallowed but is poorly absorbed from the gastrointestinal tract. Ipratropium and its metabolites are eliminated in the urine and faeces.

Ipratropium bromide monohydrate(66985-17-9)Related Product Information

• Methanol
• Ipratropium bromide
• Methyl cellulose
• Pinaverium bromide
• Sodium bromate
• METSULFURON METHYL
• Rocuronium bromide
• Calcium bromide
• 4-Methoxyphenylacetone
• Phosphorus tribromide
• Potassium bromide
• N-OCTANE
• 1-OCTANESULFONIC ACID, SODIUM SALT, MONOHYDRATE
• CHLOROPHOSPHONAZO III
• Tiotropium bromide
• Sodium bromide
• Hydrogen bromide
• Diphenyldimethoxysilane